Table 1.

Cases of Psoriasis Exacerbation Following COVID-19 Vaccination in Patients Undergoing Treatment with Biologics for Psoriasis

Authors	Patient	Sex	Vaccine/Dose	Days	Previous Treatment	New Treatment
Megna et al56	1	M	AZD1222 / 1	10	Secukinumab	Secukinumab*
	2	M	mRNABNT162b2 / 2	12	Adalimumab	Ixekizumab
	3	M	mRNABNT162b2 / 2	9	Ixekizumab	Ixekizumab*
	4	F	AZD1222 / 1	7	Guselkumab	Guselkumab*
	5	M	mRNABNT162b2 / 2	5	Secukinumab	Secukinumab*
	6	M	mRNABNT162b2 / 1	14	Etanercept	Ixekizumab
Koumaki et al57	1	F	mRNABNT162b2/2	10	Secukinumab	Secukinumab*
	2	F	mRNABNT162b2/2	2	Adalimumab	Adalimumab*
	3	F	mRNABNT162b2/1	20	Adalimumab	Oral Corticosteroids
	4	F	mRNABNT162b2/1,2	3	Secukinumab	Secukinumab
	5	F	mRNABNT162b2/1,2	7	Secukinumab	Secukinumab
	6	F	mRNABNT162b2/1	20	Ustekinumab	Ustekinumab*
Tsunoda et al58	1	M	mRNABNT162b2 / 2	3	Risankizumab	Risankizumab
Ruggiero et al59	1	M	mRNABNT162b2/2	16	Adalimumab	Brodalumab
	2	F	mRNABNT162b2/2	25	Secukinumab	Secukinumab*

Notes: AZD1222: AstraZeneca‐Oxford AZD1222. mRNA‐1273: Moderna mRNA‐1273. mRNABNT162b2: Pfizer mRNABNT162b2. Dose: number of doses after which psoriasis flare occurred. *Biologic treatment associated with topical calcipotriol/betamethasone combination and/or phototherapy.

Abbreviations: M, male; F, female.